These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15951989)

  • 1. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease.
    Sorrentino D; Avellini C; Beltrami CA; Pasqual E; Zearo E
    Int J Colorectal Dis; 2006 Apr; 21(3):276-81. PubMed ID: 15951989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease--a possible target for infliximab treatment.
    Agnholt J; Kelsen J; Brandsborg B; Jakobsen NO; Dahlerup JF
    Eur J Gastroenterol Hepatol; 2004 Jul; 16(7):649-55. PubMed ID: 15201577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis.
    Swaminath A; Lichtiger S
    Inflamm Bowel Dis; 2008 Feb; 14(2):213-6. PubMed ID: 18022870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
    Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
    Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large Bowel Progressive Stricture after Infliximab Therapy for Crohn's Disease.
    Matsueda K; Toyokawa T; Sakata M; Fujita I; Horii J
    Intern Med; 2018 Aug; 57(15):2179-2183. PubMed ID: 29526964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of postoperative recurrence of Crohn's disease by infliximab.
    Sorrentino D; Terrosu G; Avellini C; Beltrami CA; Bresadola V; Toso F
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):457-9. PubMed ID: 16538123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
    Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
    Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hemorrhagic Crohn's disease controlled with infliximab.
    Meyer MM; Levine EJ
    Inflamm Bowel Dis; 2009 Oct; 15(10):1456-7. PubMed ID: 19107774
    [No Abstract]   [Full Text] [Related]  

  • 13. Complete resolution of enterocolic fistulas with infliximab.
    Nunes J; Santos PM; Tavares L
    BioDrugs; 2010 Dec; 24 Suppl 1():28-30. PubMed ID: 21175233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal healing of ileal lesions is associated with long-term clinical remission after infliximab maintenance treatment in patients with Crohn's disease.
    Beppu T; Ono Y; Matsui T; Hirai F; Yano Y; Takatsu N; Ninomiya K; Tsurumi K; Sato Y; Takahashi H; Ookado Y; Koga A; Kinjo K; Nagahama T; Hisabe T; Takaki Y; Yao K
    Dig Endosc; 2015 Jan; 27(1):73-81. PubMed ID: 24833527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab.
    Di Sabatino A; Saarialho-Kere U; Buckley MG; Gordon JN; Biancheri P; Rovedatti L; Corazza GR; Macdonald TT; Pender SL
    Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1049-55. PubMed ID: 19357521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment.
    Ljung T; Axelsson LG; Herulf M; Lundberg JO; Hellström PM
    Aliment Pharmacol Ther; 2007 Apr; 25(8):925-32. PubMed ID: 17402996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of infliximab in the treatment of refractory inflammatory bowel disease with complication].
    Lee KM; Kim JS; Shin DH; Cheong JY; Yoo BM; Kim JK; Lee KJ; Hahm KB; Kim JH; Cho SW
    Korean J Gastroenterol; 2004 Nov; 44(5):259-66. PubMed ID: 15564805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease.
    Ferkolj I; Ihan A; Markovic S
    Hepatogastroenterology; 2005; 52(64):1128-33. PubMed ID: 16001645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.